ASCO 2025

De-escalating therapy - a step forward

Practice changing results for EBC patients?

WSG: HER2+ pooled analysis

TRADE: Abemaciclib in eBC

HRD and BRCA status as a new innovative staging system?

Risk according to NATALEE / MonarchE in WSG-ADAPT trial

Intraoperative dose escalation helps to reach targeted dose of abemaciclib

ctDNA for the early detection of molecular recurrence

SG + Pembro in aTNBC: a new standard of care?

A new standard for endocrine-resistant HR+ MBC?

SERENA-6 - a challenging strategy?

A new standard for the firstline treatment of HER2+ patients?

New compounds - new approaches: TNBC | HR+ | HER2+

Next-gen endocrine therapies and ADCs: Updates from EMBER-3 and DB-06

Triple therapy 1st line | double therapy 2nd line - new treatment options for HR+ breast cancer patients

AI and ADCs: Precision diagnostics & safer rechallenge in HER2+ breast cancer

Final OS-Analysis of INAVO-120 trial

Liquid biopsy as a navigator for personalized therapy guidance

New AKT/PIK3 Antagonist for treatment of mBC after CDK4/6 inhibitor treatment

ASCENT-04

Vepdegestrant for treatment of ER+/HER2- aBC

New treatment option in first line of metastatic TNBC

Future new SOC for PD-L1-positive mTNBC

Re-exposition and ILD

New SOC in first-line treatment for primary endocrine resistance

T-DXd: Detecting ILD and treat again

Additional ADC effective for untreated TNBC

Ipataserib + Fulvestrant improves PFS in PIK3CA-altered pathway in patients with HER2-/ER+ BC

New firstline SOC for HER2+ metastatic BC

SG + Pembrolizumab might become SOC for PD-L1-positive advanced TNBC

Sac-TMT for metastatic TNBC

Additional chemo-free option for TNBC

A new first-line therapy for TNBC

ABC for metastatic TNBC

Effective ADC for HER2+ mBC with brain metastases

OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) monotherapy vs standard-of-care for ER+, HER2- advanced or metastatic breast cancer patients after endocrine therapy and CDK4/6 inhibitors.

Un nouveau traitement de première ligne pour le TNBC

Nuovo antagonista di AKT/PIK3 per il trattamento della mBC dopo il trattamento con inibitori CDK4/6

Una nuova terapia di prima linea per il TNBC

Nuova opzione di trattamento in prima linea per il TNBC metastatico

Analisi finale della OS dello studio INAVO-120

Ipatasertib + Fulvestrant mejora la supervivencia libre de progresión en la vía alterada de PIK3CA en pacientes con cáncer de mama HER2 negativo y receptores de estrógeno positivos.

Vepdegestrant per il trattamento di ER+/HER2- aBC

SG + Pembrolizumab podría convertirse en el tratamiento estándar para el TNBC avanzado con PD-L1 positivo.

PARP-inhibitor combinations in advanced prostate cancer

A bright future? Radioligands, hormonal treatment options and bispecific T-cell engagers

The role of ARPIs in mHSPCThe role of ARPIs in mHSPC

mHSPC - ADT + NHT updates

Niraparib + Abiraterone Improves Outcomes in HRR-Mutated mCSPC

Rebirth of Rucaparib

Localized CSPC - innovations

CAN-2409 Offers First New Option in 20 Years

MMAI Model identifies patients who benfit from ARPI in STAMPEDE

Combination of LU-PSMA and immunotherapy, EVOLUTION trial

News of ANZUP trial

Immuntherapy - an evolution?

Personalized In Situ Immunotherapy SYNC-T Shows High Efficacy in mCRPC

New way of treatment for PCa

Real world data from ironman registry confirms prognostic values for PSA

Stereotactic beam radiation therapy 2.0

mHSPC - prognostification - indications on integration?

Adding EZH2 to Enzalutamide to decrease the development of antiandrogen resistance

Artera MMAI score en prediktiv biomarkör i STAMPEDE M0 studien

Real-world data från Ironman: PSA nivå en viktig prognostisk markör

Evolution: Kombination av LuPSMA och immunterapi.

ICI Combos in 1L and Maintenance – Mixed Bags or Meaningful Moves?

Sasanlimab + BCG: Practice-Changing Potential for Aggressive NMIBC

ctDNA Clearance Confirms Added Value of Perioperative Durvalumab in MIBC

Complete but Not Finished: EV+P cCR Data Extend the SOC Case

Response matters in advanced urothelial cancer patients treated with EV-Pembro

The role of sansalimab (+ SG) in BCG-naive and BCG-refractory MIBC

Update on EV-PEM in the EV-302 study

mUC - new approaches?

mUC EVP + subsequent therapies

CREST Study: Promising Results with PD-1 Inhibitor Sasanlimab in High-Risk BCG-Unresponsive NMIBC

Intensive caution of BCG Therapy

ASCO 2025 - Highlights for Bladder Cancer

NIAGARA study and circulating tumor DNA

Benefit of IO/IO therapy in mUC

UTUC - enlighted

A new prognostic factor in bladder cancer?: The case of ctDNA

New nectin-4 ADCs are coming

New option for high-risk NMIBC

La respuesta es importante en pacientes con cáncer urotelial avanzado tratados con EV-Pembro

HIF alfa sigue siendo una diana interesante en el RCC y otras enfermedades causadas por VHL

El rol de sansalimab (+ SG) en el carcinoma urotelial muscularmente invasivo en pacientes naïve y refractarios al tratamiento con BCG.

De nouveaux ADC pour la nectine-4 arrivent

¿Un nuevo factor pronóstico en el cáncer de vejiga? El caso del ctDNA

ASCO 2025 - Στιγμιότυπα για τον καρκίνο της ουροδόχου κύστης

Who Really Benefits? Pembro’s Solid, Atezo’s Still Digging for Answers

Casdatifan + Cabo – Too Early to Call It a Game Changer?

9 Years of CheckMate 214 – Is Nivo + Ipi Still Holding Up?

PDIGREE: Real-Life Answers for Post-Ipi/Nivo Decisions

Nivo + Ipi - Update & Insights

First lession

Long-term outcome of Nnivo-Ipi in clear cell RCC

Allogeneic CD70 CAR T Cells in refractory RCC

HIF alpha still an interesting target in RCC and other VHL driven diseases

5-Year OS data from the KEYNOTE-564 study

Zanzalitinib + Nivolumab +/- Relatlimab in Front-line mRCC

Neoadjuvant Approaches in resectable NSCLC: Insights from CheckMate 816 and NeoADAURA

New synergies? Radiotherapy and IO in Limited-Stage SCLC and Unresectable Stage III NSCLC

Chemoimmunotherapy followed by chemoradiotherapy

Updates in perioperative strategies in NSCLC

Neadjuvant targeted therapy

cTDNA in periop chemo-IO strategies

Neoadjuvant Alectinib in resectable stage III NSCLC

ctDNA stratification

MRD-analysis of the AEGEAN-trial

CheckMate 816: Update on OS-benefit

CM-816: The OS results are positive and demonstrate that chemo-IO should be administered prior to surgery

CheckMate 816 : Mise à jour sur les avantages du système d'exploitation

CM-816 : Les résultats de l'OS sont positifs et démontrent que la chemo-IO doit être administrée avant l'intervention chirurgicale

Actualizaciones en estrategias perioperatorias en NSCLC

New options in First-Line Therapy in metastatic NSCLC

Targeting rare mutations in metastatic NSCLC - HER2 and EGFR Exon 20

What is the future in the field of EGFR resistance?

Time of day of immunotherapy is important

HERTHENA-Lung02 unfortunately negative study - withdrawal of licence application

TROP2 targets – where is first-line development heading?

KRAS G12C: Can immunotherapy improve patient outcome alone?

Updates on ADCs in EGFR resistance

Immunotherapy – before or after 3 p.m.?

HER3-DXd: dissapointing negative trial

GDPase-Inhibition 1st line in KRAS G12C Mut.: Improved outcome?

ADC as 3L in EGFR

Sevarbertinib – an additional option for HER2 exon 20 alterations

Benefit of IO is depending on the time of day of administration

Does the timing of IO-infusion impact survival?

RELA-104-biomarker-analysis

ADC in the 3L beats docetaxel

Have we MET our target?

Is there still a place for HER3-DXd in advanced NSCLC?

Hebben we ons doel gehaald?

Actualizaciones sobre los ADC en la resistencia al EGFR

Is er nog een plaats voor HER3-DXd in gevorderd NSCLC?

HERTHENA-Lung02 étude malheureusement négative - retrait de la demande d'autorisation

KRAS G12C: Kan immunotherapie alleen het resultaat voor de patiënt verbeteren?

Redefining SCLC: Lubri/Atezo maintenance in 1L, Tarlatamab as new SOC in 2L, and a new trispecific T-cell Engager

The first positive maintenance therapy in SCLC

DeLLphi-304: Dramatic change in 2L-treatment in SCLC

New maintenance therapy for SCLC

Tarlatamab - a new SOC in second line

Taralatamb - the new SOC in 2L treatment

New therapies to improve patient survival

DeLLphi-304 : Changement radical dans le traitement de deuxième ligne du cancer du SCLC

De nouvelles thérapies pour améliorer la survie des patients

LA HNSCC - New neoadjuvant SOC

Exercise - The new old wonderdrug